Law360 (November 14, 2018, 3:50 PM EST) -- Health benefits providers that refunded members for the cost of Allergan’s dry-eye medication Restasis will be able to move forward on the majority of the state law claims the drugmaker wanted thrown out, a New York federal judge overseeing multidistrict antitrust litigation has ruled.
In an order filed Tuesday, U.S. District Judge Nina Gershon gave a partial win to the end-payors, keeping alive six of eight state antitrust claims that Allergan PLC had moved to shut down in the sprawling litigation accusing the company of taking extraordinary actions to keep Restasis — which earned $1.4 billion last year — from facing...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!